Literature DB >> 17120595

Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus.

K de Leeuw1, B Freire, A J Smit, H Bootsma, C G Kallenberg, M Bijl.   

Abstract

To determine risk factors of accelerated atherosclerosis in patients with systemic lupus erythematosus (SLE), 72 patients with inactive disease and 36 age- and sex-matched controls were included. The intima-media thickness (IMT) of the common carotid artery was determined by ultrasound. Traditional risk factors and disease-related factors were recorded. Cardiovascular risk was estimated using SCORE (systematic coronary risk evaluation). Markers of inflammation, endothelial activation and vascular remodelling (matrix metalloproteinases (MMP-3, MMP-9) and tissue inhibitor of metalloproteinase- 1 (TIMP- 1)) were determined. IMT was increased in patients (0.67 mm+/-0.13 versus 0.61 mm+/-0.11, P < 0.05). Prevalence of hypertension (33% versus 6%, P < 0.001), SCORE (2.2 (1.7-4.2) versus 1.7 (1.3-2.1), P < 0.001), as well as parameters of inflammation (CRP 1.8 (0.6-5.8) mg/L versus 0.6 (0.2-1.0) mg/L, P < 0.001) and endothelial activation (VCAM-1 505 (389-683) ng/mL versus 374 (322-427) ng/mL, P < 0.001) and von Willebrand factor (138 (59-208)% versus 48 (24-92)%, P < 0.001), were increased in patients. Vascular remodelling was altered: MMP-3 and TIMP-1 were increased (18 (10-29) ng/mL versus 8 (5-11) ng/mL, P < 0.001, and 275 (216-352) ng/mL versus 230 (197-268) ng/mL, P < 0.001, respectively), and MMP-9 was decreased in SLE (266 (147-412) ng/mL versus 348 (226-530) ng/mL, P < 0.05). Univariate analyses revealed that in patients IMT was associated with age, systolic blood pressure, SCORE and disease duration. In multivariate analysis, age and SCORE were independent predictors of IMT. In conclusion, SLE patients have an increased IMT, which is associated with traditional risk factors. Non-traditional risk factors, such as endothelial activation, altered vascular remodelling and disease duration, might play an additional role.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120595     DOI: 10.1177/0961203306069972

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  31 in total

Review 1.  The role of antimalarial agents in the treatment of SLE and lupus nephritis.

Authors:  Senq-J Lee; Earl Silverman; Joanne M Bargman
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

2.  Atherosclerosis in Systemic Sclerosis: a Modern Controversy.

Authors:  Stefania L Magda; Raluca I Mincu; Carmen M Mihai; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Buchar)       Date:  2015-09

3.  Metabolic syndrome in systemic lupus erythematosus: lower prevalence in Brazil than in the USA.

Authors:  George D Azevedo; Rafael G N Gadelha; Maria José Vilar
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

4.  Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus.

Authors:  Konstantinos Tziomalos; Ioannis Gkougkourelas; Alexandros Sarantopoulos; Eleni Bekiari; Evangelia Makri; Nikolaos Raptis; Konstantinos Tselios; Marianna Pantoura; Apostolos I Hatzitolios; Panagiota Boura
Journal:  Rheumatol Int       Date:  2016-11-21       Impact factor: 2.631

5.  Prevalence of metabolic syndrome in a cohort of systemic lupus erythematosus patients from Northeastern Brazil: association with disease activity, nephritis, smoking, and age.

Authors:  Marta Maria das Chagas Medeiros; Ídila Mont'Alverne Xavier de Oliveira; Ádilla Thaysa Mendes Ribeiro
Journal:  Rheumatol Int       Date:  2015-07-07       Impact factor: 2.631

Review 6.  Mortality in Systemic Lupus Erythematosus: an Updated Review.

Authors:  César E Fors Nieves; Peter M Izmirly
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

7.  Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years.

Authors:  Adnan N Kiani; Laurence S Magder; Michelle Petri
Journal:  Rheumatol Int       Date:  2011-07-27       Impact factor: 2.631

Review 8.  Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome.

Authors:  Paul R J Ames; Annamaria Margarita; Jose Delgado Alves
Journal:  Clin Rev Allergy Immunol       Date:  2009-08       Impact factor: 8.667

9.  Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge.

Authors:  Irene Em Bultink
Journal:  Arthritis Res Ther       Date:  2010-02-22       Impact factor: 5.156

10.  The evaluation of carotid intima-media thickness in children with familial Mediterranean fever.

Authors:  Harun Peru; Bülent Altun; Mustafa Doğan; Fatih Kara; Ahmet Midhat Elmaci; Bülent Oran
Journal:  Clin Rheumatol       Date:  2007-10-10       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.